The blood tests are based on Lucence’s proprietary liquid biopsy technology, which detect genetic mutations from tumor DNA circulating in the blood. This allows doctors to identify the cancer mutation and select the best treatment for their patients. The tests are simple to administer and non-invasive as compared to conventional tissue biopsy, which requires surgical removal of tissue from the body. The turnaround time for these test results is also shorter with results coming back in days instead of over a week for current approaches. This allows doctors to make more timely treatment decisions. The tests can detect common cancers in Asia like lung and colon cancer.
Lucence’s blood test can also diagnose early stage nasopharyngeal cancer before symptoms show. In Asia, nasopharyngeal cancer accounts for more than 80% of all cases in the world, with the highest prevalence in Singapore and Malaysia. The test detects a DNA fragment of the Epstein-Barr virus called BamHI-W even if they are in minute amounts. This virus is found in almost all patients with nasopharyngeal cancer.
Additionally, Lucence’s blood tests can also determine whether a person is predisposed to cancer by detecting genes commonly associated with increased risk of cancer, for example, the BRCA1 and BRCA2 genes for breast and ovarian cancers. This test identifies people with a higher than average risk of developing cancer. These people can benefit from additional surveillance and preventive measures to bring down their risks of developing cancer.
Quest provides laboratory testing services to clinicians, hospitals, medical centers and their patients through the deployment of advanced diagnostic testing methods and technology. With this partnership, Lucence’s full range of cancer blood tests will now be made available to Quest’s customers. The testing will be supported by Lucence’s ISO15189:2012 accredited molecular diagnostics laboratory.
“We are delighted to announce the availability of Lucence’s non-invasive liquid biopsy technology to our customers. With this partnership, doctors can now select better cancer treatments and detection for their patients with a range of blood tests. We look forward to advancing precision medicine through personalized diagnostics with Lucence in Singapore and the region,” said Ms. Jessica Chua, CEO, Quest Laboratories.
“We are excited to partner a global medical laboratory like Quest to provide our liquid biopsy tests with a focus on Asian patients and cancers. We see Quest as a priority partner in achieving better cancer care for patients in Singapore and Asia. Most importantly, this collaboration will help us to fight cancer by earlier diagnosis and treatment,” said Dr. Min-Han Tan, Founder and CEO, Lucence Diagnostics.
For further information, please contact:
Email: [email protected]
About Lucence Diagnostics
Lucence Diagnostics is a clinical genetics company with the mission of fighting cancer through deep innovation. Headquartered in Singapore with operations and partners in Hong Kong and ASEAN, Lucence invents genetic tests for cancer physicians to select the right treatment for their patients. Lucence’s tests target the most common cancers in the world powered by its patented sequencing technology and in-house clinical analytics. Its key operations are supported by an ISO15189:2012 accredited molecular diagnostics laboratory and a clinical cancer genetics medical center.
For more information please visit: www.lucencedx.com
About Quest Laboratories
Quest Laboratories is the largest independent, private medical laboratory in Singapore. The first full-service private laboratory in the country with dual accreditation from the College of American Pathologists (CAP) and the Singapore Accreditation Council (SAC-SINGLAS ISO 15189), Quest offers a full suite of laboratory tests in Histopathology, Cytopathology, Biochemistry, Haematology, Microbiology, Immunology, Serology, Special Chemistry, and Industrial Toxicology. Quest is part of Healthscope, one of Australia’s leading providers of integrated healthcare with over 40 private hospitals, along with international pathology facilities in New Zealand, Singapore, Malaysia, and Vietnam.
Please visit www.questlabs.com.sg.